Tag Archives: Craig Bijou

Cantor Fitzgerald Remains a Buy on Viewray (VRAY)

Cantor Fitzgerald analyst Craig Bijou reiterated a Buy rating on Viewray (VRAY – Research Report) yesterday and set a price target of $13. The company’s shares closed yesterday at $6.77. Bijou said: “: We reiterate our Overweight rating and $13

NuVasive (NUVA) Gets a Hold Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Craig Bijou maintained a Hold rating on NuVasive (NUVA – Research Report) yesterday and set a price target of $61. The company’s shares closed yesterday at $60.60. Bijou noted: “: We maintain our Neutral rating on NUVA,

Cantor Fitzgerald Sticks to Their Buy Rating for SeaSpine Holdings (SPNE)

In a report released yesterday, Craig Bijou from Cantor Fitzgerald reiterated a Buy rating on SeaSpine Holdings (SPNE – Research Report), with a price target of $22. The company’s shares closed yesterday at $14.38. Bijou noted: “: We reiterate our

Cantor Fitzgerald Thinks Ra Medical Systems Inc’s Stock is Going to Recover

Cantor Fitzgerald analyst Craig Bijou reiterated a Buy rating on Ra Medical Systems Inc (RMED – Research Report) yesterday and set a price target of $11. The company’s shares closed yesterday at $3.96, close to its 52-week low of $3.76.

Cantor Fitzgerald Sticks to Their Buy Rating for Globus Medical (GMED)

In a report released today, Craig Bijou from Cantor Fitzgerald reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of $60. The company’s shares opened today at $49. Bijou commented: “We reiterate our Overweight

Integra Lifesciences (IART) Gets a Hold Rating from Cantor Fitzgerald

In a report released today, Craig Bijou from Cantor Fitzgerald maintained a Hold rating on Integra Lifesciences (IART – Research Report), with a price target of $50. The company’s shares closed yesterday at $51.93. Bijou commented: “We maintain our Neutral